CAY10505 can inhibit PI3K-gamma with IC50 of 33 nM.
In vivo
Five weeks of DOCA administration were followed by 7 days of daily administration of PI3K-gamma inhibitor (5-[[5-(4-fluorophenyl)-2-furanyl]methylene]-2,4-thiazolidinedione (CAY10505), 0.6 mg.kg(-1), per os (p.o.)), atorvastatin (30 mg.kg(-1), p.o.), and losartan (25 mg.kg(-1), p.o.) (positive control of hypertension), which significantly improved acetylcholine-induced endothelium dependent relaxation, serum nitrate and (or) nitrite level, glutathione level, and the vascular endothelial lining in hypertensive rats.